BTAI - BioXcel Therapeutics Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

72.11M

Cash

74.14M

Avg Qtr Burn

-30.09M

Short % of Float

2.43%

Insider Ownership

21.78%

Institutional Own.

34.28%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IGALMI (dexmedetomidine) (BXCL501) Details Mental health, Bipolar depression, Schizophrenia, Bipolar disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Mental health, Schizophrenia, Bipolar depression, Bipolar disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL701 + KEYTRUDA Details Neuroendocrine prostate cancer, Castration-resistant prostate cancer	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL701 + KEYTRUDA Details Solid tumor/s, Cancer, Pancreatic cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 + Duloxetine Details Major depressive disorder	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Opioid use disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BXCL501 Details Mental health, Delirium, Agitation	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.